Regulating gene therapies: what can be learned from COVID-19?

admin_vjr_user — Fri, 30 Apr 2021 10:09:58 +0000

Nicole Faust, PhD, CEVEC Pharmaceuticals, Koeln, Germany, discusses the potential impact of the COVID-19 pandemic on the regulation of gene therapies. The use of gene therapy technologies in the development of vaccines for COVID-19 and their administration in a large number of people is expected to improve understanding on the use and safety of gene therapies. In addition, experience gained from their wide-scale manufacture and the knowledge obtained on chemistry, manufacturing, and controls (CMC) processes will likely facilitate the regulation of gene therapies in the future and potentially lead to more rapid approvals. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

The future impact of COVID-19 on the gene therapy sector

admin_vjr_user — Wed, 14 Apr 2021 08:59:35 +0000

Nicole Faust, PhD, CEVEC Pharmaceuticals, Koeln, Germany, discusses the potential future impact of COVID-19 pandemic on the gene therapy sector, given that a number of recently approved adenoviral-based and mRNA COVID-19 vaccines utilize gene therapy technologies. As well as an increased understanding of gene vector technology, lessons learned from the unprecedented speed and scale at which these COVID-19 vaccines have been manufactured and distributed will be beneficial for gene therapy research and could be applied to other therapies in the future. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Nicole Faust – VJRegenMed

Regulating gene therapies: what can be learned from COVID-19?

The future impact of COVID-19 on the gene therapy sector